Dr Lalchandani Labs (BOM:541299) LT-Debt-to-Total-Asset : 0.02 (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dr Lalchandani Labs LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Dr Lalchandani Labs's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.02.

Dr Lalchandani Labs's long-term debt to total assets ratio declined from Mar. 2023 (0.19) to Mar. 2024 (0.02). It may suggest that Dr Lalchandani Labs is progressively becoming less dependent on debt to grow their business.

Dr Lalchandani Labs LT-Debt-to-Total-Asset Historical Data

The historical data trend for Dr Lalchandani Labs's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Lalchandani Labs LT-Debt-to-Total-Asset Chart

Dr Lalchandani Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.12

0.17

0.14

0.19

0.02

Dr Lalchandani Labs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial														0.14	0.30	0.19	0.18	0.02

Dr Lalchandani Labs LT-Debt-to-Total-Asset Calculation

Dr Lalchandani Labs's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	2.629	/	149.917
	=	0.02

Dr Lalchandani Labs's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	2.629	/	149.917
	=	0.02

Dr Lalchandani Labs (BOM:541299) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Dr Lalchandani Labs LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Dr Lalchandani Labs's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Lalchandani Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr Lalchandani Labs Ltd (BOM:541299) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Greater Kailash, Part-1, M-20, Basement, South Delhi, New Delhi, IND, 110048

Website

https://www.lalchandanipathlab.com

Dr Lalchandani Labs Ltd engages in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunology, virology, cytology, and other pathological and radiological investigations. It also offers Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA, and Genetic Testing. The company operates in two segments B2B sales and B2C sales, out of which the majority is from B2C sales. Revenue is generated from the sale of services.

Dr Lalchandani Labs Headlines

No Headlines